{
    "id": 1667,
    "fullName": "KIT L576P",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT L576P lies within the juxtamembrane domain (exon 11) of the Kit protein (PMID: 17372901). L576P confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit, and is transforming in cell culture (PMID: 17372901).",
            "references": [
                {
                    "id": 695,
                    "pubMedId": 17372901,
                    "title": "L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17372901"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "L576P",
    "createDate": "09/11/2014",
    "updateDate": "05/14/2019",
    "referenceTranscriptCoordinates": {
        "id": 136346,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54727495T>C",
        "cDna": "c.1727T>C",
        "protein": "p.L576P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7765,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 4517,
                "therapyName": "Bevacizumab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6478,
                    "pubMedId": 25363205,
                    "title": "Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12288,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT L576P in culture (PMID: 29035277).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8609,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two patients with melanoma harboring KIT L576P, one who had progressed on Gleevec (imatinib), demonstrated initial clinical benefit following treatment with Sprycel (dasatinib); however, one patient progressed after 3 months, and the other patient progressed after 4 months of treatment (PMID: 19671763).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6696,
                    "pubMedId": 19671763,
                    "title": "Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19671763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8615,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment resulted in initial tumor reduction, but was followed by disease progression at all tumor sites in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 6700,
                    "pubMedId": 20372153,
                    "title": "Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20372153"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11231,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including three melanoma patients harboring KIT L576P demonstrating a partial response (PMID: 28327988).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12291,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cells harboring KIT L576P in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 6429,
                "therapyName": "SEL201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17523,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT L576P in culture (PMID: 31205508).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11232,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient co-harboring KIT L576P and KIT W557R demonstrating a partial response and a progression free survival of 5.3 months and overall survival of 14.7 months when treated with Tasigna (nilotinib) (PMID: 28327988).",
            "molecularProfile": {
                "id": 27931,
                "profileName": "KIT W557R KIT L576P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1670,
            "profileName": "KIT L576P",
            "profileTreatmentApproaches": [
                {
                    "id": 1489,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT L576P"
                }
            ]
        },
        {
            "id": 27931,
            "profileName": "KIT W557R KIT L576P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136347,
            "transcript": "XM_017008178",
            "gDna": "chr4:g.54727495T>C",
            "cDna": "c.1727T>C",
            "protein": "p.L576P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136346,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54727495T>C",
            "cDna": "c.1727T>C",
            "protein": "p.L576P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}